肾移植何时开始吃雷帕鸣

How effective is (sirolimus) in the treatment of kidney transplantation? As we all know, uremia is a very serious disease that can endanger people's lives, and patients must be treated in time. Kidney transplantation is a surgical method to treat uremia, but after kidney transplantation, patients will experience rejection, which will affect human health. Rapamin (sirolimus) is a medicine used to prevent rejection reactions.

So many patients don’t know how to take rapamycin (sirolimus). Now I will introduce it to you.

Rapamin (sirolimus) is recommended for combined use with cyclosporine and corticosteroids. Take orally, once daily. It should be started as soon as possible after transplantation. For new transplant recipients, the loading dose should be taken, which is 3 times the maintenance dose. The recommended loading dose for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day. Although the loading dose of 15 mg and the maintenance dose of 5 mg/day used in clinical trials are satisfactory, the therapeutic benefit of doses above 2 mg is unclear for kidney transplant patients.

Daily administration of rapamin (sirolimus) is recommended in combination with cyclosporine and corticosteroids. Take orally, once daily. It should be started as soon as possible after transplantation. For new transplant recipients, the loading dose should be taken, which is 3 times the maintenance dose. The recommended loading dose for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day. Although the loading dose of 15 mg and the maintenance dose of 5 mg/day used in clinical trials are satisfactory, the therapeutic benefit of doses above 2 mg is unclear for kidney transplant patients. Patients taking rapamycin (sirolimus) 2 mg daily had overall better health than those taking rapamin (sirolimus) 5 mg daily.

Sirolimus, the main component of Rapamin (sirolimus), inhibits the activation and proliferation of T lymphocytes stimulated by antigens and cytokines (interleukins IL-2, IL-4 and IL-15). It also inhibits the production of antibodies. In cells, sirolimus binds to the immunophilin, FK-binding protein-12 (FKBP-12), to generate the FKBP-12 immunosuppressive complex. This complex binds to the mammalian sirolimus BA molecule (mTOR, a key regulatory kinase) and inhibits its activity, thereby inhibiting the progression from the G1 phase to the S phase in the cell cycle.

The above is the (sirolimus) taking guide, I hope it can help everyone.